Stock AnalizIqvia Holdings Inc. IQV
Biotechnology: Commercial Physical & Biological Resarch · IPO 2013 · data as of November 13, 2026
Iqvia Holdings Inc. (IQV) is a healthcare company listed in the US with a market value of about $43.7B. In the twelve months to September 30, 2026 it had revenue of $17.3B and net income of $1.4B, a net margin of 8.1%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is track record (3/5); the weakest is future growth (0/5).
Key numbers: a P/E of 32.3, a price to free cash flow of 21.0, 5-year revenue growth of 8% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.
Score: 1.6 / 5
Checks passed
- PEG below 1.5
- 5-year EPS growth above 10% a year
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3B | $16.3B | $15.4B | $15.0B | $14.4B | $13.9B | $11.4B | $11.1B | $10.4B | $9.7B | $6.9B |
| Net income | $1.4B | $1.4B | $1.4B | $1.4B | $1.1B | $966M | $279M | $191M | $259M | $1.3B | $72M |
| Free cash flow | $2.1B | $2.1B | $2.1B | $1.5B | $1.6B | $2.3B | $1.3B | $835M | $795M | $601M | $696M |
| EPS (diluted) | $8.22 | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 |
| Net margin | 8.1% | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | 2.5% | 1.7% | 2.5% | 13.1% | 1.1% |
| ROIC | — | 8.1% | 8.8% | 9.1% | 7.7% | 6.4% | 3.1% | 2.9% | 3.4% | 2.9% | 2.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 18 analysts is $311.89, 18% above the current price; targets range from $268.00 to $346.00; the consensus rating is “Strong buy”; expected EPS is $12.96 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Iqvia’s P/E ratio?
About 32.3, based on the last twelve months of diluted earnings per share (forward P/E about 19.2).
Is Iqvia stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Iqvia pay a dividend?
Not currently.
Is Iqvia a good stock to buy?
We do not give buy or sell advice. Iqvia scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.